News

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.
Jemperli is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
GSK ’s GSK -1.42% cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant’s oncology ...
While Jemperli is not yet approved for the treatment of locally advanced dMMR/MSI-H rectal cancer, it is currently indicated in the US for certain patients with advanced or recurrent endometrial ...
GSK plc announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for ...
Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes ...
Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases Jemperli plus chemotherapy demonstrated a statistically significant and clinically meaningful ...
The FDA's approval of GSK's Jemperli for the treatment of endometrial cancer represents a significant step forward for the pharmaceutical giant and could potentially impact its financial performance.